amyloid
Alzheimer’s treatment hopes take another dive as Roche drug fails trial
Phil Taylor
Alzheimer's disease, amyloid, Biogen, Eisai, gantenerumab, Genentech, lecanemab, neurology, Roche
0 Comment
Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial
Phil Taylor
AC Immune, Alzheimer's disease, amyloid, crenezumab, gantenerumab, Genentech, Roche
0 Comment
Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go
Phil Taylor
Aduhelm, Alzheimer's disease, amyloid, Biogen, Eisai, lecanemab, regulatory
0 Comment
News/ News/ Sales and Marketing
CMS decision on Aduhelm is in, and it’s bad news for Biogen
Phil Taylor
Aduhelm, Alzheimer's disease, amyloid, Biogen, Medicare
0 Comment
BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody
Phil Taylor
Alzheimer's disease, amyloid, antibody, Bristol-Myers Squibb, donanemab, Eli Lilly, neurology, Prothena, Tau
0 Comment
Double resignation over Aduhelm approval depletes FDA’s CNS adcomm
Phil Taylor
aducanumab, Aduhelm, Alzheimer's, amyloid, Biogen, central nervous system, fda, neurology, regulatory
0 Comment
Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab
Phil Taylor
aducanumab, Aduhelm, Alzheimer's disease, amyloid, Biogen, fda, neurology
0 Comment
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?
Phil Taylor
aducanumab, Alzheimer's disease, amyloid, Biogen, donanemab, Eisai, Eli Lilly, neurology
0 Comment